Actively Recruiting
Examining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE)
Led by University of California, San Francisco · Updated on 2026-04-24
50
Participants Needed
1
Research Sites
143 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This randomized, placebo-controlled crossover trial will test the feasibility and acceptability of using colesevelam in male firefighters with high per- and polyfluoroalkyl substances (PFAS) exposure. This trial will also explore whether colesevelam lowers blood PFAS levels and urine environmental toxicant and mold mycotoxin levels.
CONDITIONS
Official Title
Examining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male firefighter, active or retired
- California resident
- Age 18 or older
- English-speaking
- Access to a reliable internet connection
- Willing to attend 3 in-person study visits in the San Francisco Bay Area over about 6.5 months
- Willing to receive weekly text message reminders to complete online surveys
- Willing to complete a mail-based, at-home finger-prick blood test
- Willing to take 3 tablets (each tablet about the size of a multivitamin) orally twice daily for a total of 6 months
- Evaluated by study team to have an elevated risk of PFAS exposure (e.g., duration of firefighting service, prior NASEM-7 result greater than or equal to 10 ng/mL)
You will not qualify if you...
- Gastroparesis or other severe gastrointestinal motility disorders
- Bowel obstruction
- History of major gastrointestinal tract surgery
- Dysphagia or difficulty swallowing (due to tablet size)
- History of hypertriglyceridemia (triglycerides exceeding 500 mg/dL)
- History of hypertriglyceridemia-induced pancreatitis
- Type 1 or 2 diabetes
- History of fat-soluble vitamin deficiencies, i.e., vitamins A, D, E, or K
- Phenylketonuria
- History of known bleeding/clotting disorders
- Medications or treatments that may impact the excretion of PFAS, such as activated charcoal, other bile acid sequestrants, chelation therapies, etc.
- Unalterable plans to donate blood or plasma during the study participation period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UCSF Osher Center for Integrative Health
San Francisco, California, United States, 94115
Actively Recruiting
Research Team
A
Ashley Mason, PhD
CONTACT
L
Leena Pandya, ND
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here